Trisalus Life Sciences Inc has entered into a Credit Agreement providing a $50 million credit facility, of which $25 million has been borrowed, and $10 million was received from the Second Tranche on February 18, 2025, with warrants issued for 91,263 shares at an exercise price of $5.4787.